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Background: Attenuated positive psychotic symptoms represent the defining features
of the clinical high-risk for psychosis (CHR-P) criteria. The effectiveness of each available
treatment for reducing attenuated positive psychotic symptoms remains undetermined.
This network meta-analysis (NMA) investigates the consistency and magnitude of the
effects of treatments on attenuated positive psychotic symptoms in CHR-P individuals,
weighting the findings for acceptability.
Methods: Web of Science (MEDLINE), PsycInfo, CENTRAL and unpublished/gray
literature were searched up to July 18, 2017. Randomized controlled trials in CHR-P
individuals, comparing at least two interventions and reporting on attenuated positive
psychotic symptoms at follow-up were included, following PRISMA guidelines. The
primary outcome (efficacy) was level of attenuated positive psychotic symptoms at 6 and
12 months; effect sizes reported as standardized mean difference (SMD) and 95% CIs in
mean follow-up scores between two compared interventions. The secondary outcome
was treatment acceptability [reported as odds ratio (OR)]. NMAs were conducted for both
primary and secondary outcomes. Treatments were cluster-ranked by surface under the
cumulative ranking curve values for efficacy and acceptability. Assessments of biases,
assumptions, sensitivity analyses and complementary pairwise meta-analyses for the
primary outcome were also conducted.
Results: Overall, 1,707 patients from 14 studies (57% male, mean age = 20)
were included, representing the largest evidence synthesis of the effect of preventive
treatments on attenuated positive psychotic symptoms to date. In the NMA for
efficacy, ziprasidone + Needs-Based Intervention (NBI) was found to be superior to
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NBI (SMD = −1.10, 95% CI −2.04 to −0.15), Cognitive Behavioral Therapy-French
and Morrison protocol (CBT-F) + NBI (SMD = −1.03, 95% CI −2.05 to −0.01), and
risperidone + CBT-F + NBI (SMD = −1.18, 95% CI −2.29 to −0.07) at 6 months.
However, these findings did not survive sensitivity analyses. For acceptability, aripiprazole
+NBI was significantly more acceptable than olanzapine+NBI (OR= 3.73; 95%CI 1.01
to 13.81) at 12 months only. No further significant NMA effects were observed at 6 or 12
months. The results were not affected by inconsistency or evident small-study effects,
but only two studies had an overall low risk of bias.
Conclusion: On the basis of the current literature, there is no robust evidence to favor
any specific intervention for improving attenuated positive psychotic symptoms in CHR-P
individuals.
Keywords: psychosis, risk, interventions, symptoms, network meta-analysis, treatments
INTRODUCTION
Indicated prevention in people at Clinical High Risk for Psychosis
(hereafter CHR-P) (1) represents one of the first attempts to alter
the course of the most severe psychiatric disorder and thereby
improve the lives of many young people (2, 3). Recent meta-
analytical evidence has suggested that it is potentially the only
effective way to reduce the duration of untreated psychosis, which
is a key factor determining outcomes (4). CHR-P individuals
accumulate several risk factors for psychosis (5), leading to
subtle symptoms (6) and functional impairments (7) that trigger
help-seeking behaviors (8). CHR-P individuals have around
20% risk [eTable 4 from Fusar-Poli et al. (9)] of developing
psychosis [but not any other non-psychotic disorder (10, 11)]
at 2 years. After two decades of CHR-P research, the paradigm
is at standstill (12). The principal limitations of knowledge are:
(i) poor penetrance of detection strategies for identifying at-
risk individuals (13, 14), (ii) the prognostic accuracy of CHR-
P tools in clinical use (15) being substantially dependent on
idiosyncratic sampling and recruitment strategies (16–20), and
(iii) an unclear effect of preventive treatments. Our research
group has previously addressed the first two limitations, and
only more recently have we completed a meta-analysis that
has investigated the consistency and magnitude of the effects
of treatments to prevent psychosis in CHR-P individuals. We
used a network meta-analytic approach, which allows head-to-
head comparisons to be performed across different preventive
treatments, and which is the recommended evidence synthesis
method for informing treatment guidelines (21). The key result
of our analysis was that there is no evidence to favor any
specific preventive treatment for CHR-P individuals over any
others (22). This finding is not completely surprising, given that
all of the most recent trials in this area were negative (23–
31). Therefore, currently, there is no convincing evidence that
indicated interventions implemented in CHR-P individuals can
effectively prevent the onset of psychosis. The impact of available
preventive interventions on the underlying neurobiology that
characterizes the CHR-P state and the onset of psychosis is
similarly unclear (3). We have fully discussed these findings
and the limitations of our analysis in our previous report (22).
Here, we complement our previous meta-analysis by focusing
on outcomes other than the onset of new psychotic disorders.
It is indeed apparent that CHR-P individuals may present with
problems other than the development of psychosis at follow-up,
such as the persistence of subthreshold psychotic symptoms (32).
In particular, attenuated positive psychotic symptoms represent
the defining features of the core CHR-P criteria. Meta-analytical
evidence indicates that around 85% (95% CI 79% to 90%) of
CHR-P individuals meet the intake criteria because of attenuated
positive psychotic symptoms [see eFigure 1 in Fusar-Poli et al.
(9)]. The severity and frequency of attenuated positive psychotic
symptoms are carefully measured by experienced clinicians using
specific semi-structured [and not self-administered (33)] CHR-
P instruments (34). Investigating the effect of treatments on
attenuated positive psychotic symptoms may also be associated
with empirical research benefits. For example, it has been
suggested that using continuous outcomes -such as attenuated
positive psychotic symptoms- rather than the binary transition
to psychosis may overcome the problems of arbitrary thresholds
defining a categorical onset of psychosis (35). Investigating
the impact of interventions on attenuated positive psychotic
symptoms is also relevant for informing clinical guidelines. For
example, the National Institute for Health and Care Excellence
(NICE) guidelines recommend cognitive behavioral therapies
(CBT) for presenting symptoms (36), but there is no clear
evidence which can reliably support this recommendation. The
other relevant outcome for CHR-P individuals is the acceptability
of treatments. Given the relatively high proportion of false
positives with respect to transition to psychosis, it is essential that
treatments have a benign side effect profile, are well tolerated and
acceptable to this patient group.
To address these gaps in knowledge, we present here a network
meta-analysis investigating the consistency and magnitude of
the effects of preventive treatments for reducing attenuated
positive psychotic symptoms in CHR-P individuals, weighting
the findings for acceptability.We focus on randomized controlled
trials (RCTs) to avoid the selection biases associated with
observational studies. Our primary aim was to test whether any
specific treatments are any more or less effective (compared to
any others) in improving attenuated positive psychotic symptoms
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in CHR-P individuals, and to provide an evidence-based ranking
of treatments on the basis of efficacy and acceptability. We
intended that this work would contribute to the rigorous
evidence-based assessment of the strengths and limitations of
the CHR-P paradigm (12). Our overarching vision is that by
understanding the limitations of current knowledge—which is
an essential prerequisite to finding ways of overcoming them—
the CHR-P field can advance with the development of refined
approaches that may ultimately achieve an effective prevention
of psychosis.
METHODS
Included Interventions
In a first step we listed the preventive interventions of
interest. The current study included all RCTs involving
non-pharmacological and/or pharmacological interventions
administered to CHR-P individuals. We focused on the following
types of treatments: CBT (different protocols), integrated
psychological therapies, psychoeducational interventions,
supportive counseling, family therapy, needs-based interventions
(NBI), antipsychotic molecules (aripiprazole, ziprasidone,
risperidone, olanzapine) and any novel/experimental
therapeutics (D-serine and omega-3 fatty acids). Although
these interventions had been defined a priori, we also allowed
the inclusion of additional treatments that were emerging
from the most recent literature search. In a second step, we
carefully reviewed the available systematic reviews and meta-
analyses to operationalize specific definitions of the preventive
treatments in CHR-P individuals. This is an essential step to
address heterogeneity across different types of interventions
and to characterize the specific nodes that were composing our
network. We defined each treatment component as indicated in
the following paragraphs.
Needs-Based Interventions (NBI)
CHR-P individuals enrolled in clinical trials are traditionally
young people who are experiencing subtle symptoms and
functional impairment (7) and who are therefore seeking help
for their problems (8). Accordingly, it is felt unethical to
randomize them to a pure placebo or “no treatment” condition
(37). In this scenario it is also difficult to provide an exact
definition of “treatment as usual,” because although treatment
guidelines do exist (36), in reality treatment implementation
is determined by local health service priorities, resources and
configurations as well as availability of specialist training. We
therefore decided on a pragmatic approach and adopted the
operationalization of NBI provided by the founders of the CHR-
P paradigm (38). This definition focuses on the symptoms
and problems already presented by the help-seeking individual
(39), and may encompass any of the following components: (a)
needs-based supportive psychotherapy for problems with, for
example, relationships, work or family; (b) case management
for resolving issues with education, housing or employment; (c)
brief family psychoeducation and general advice; (d) different
types of medications other than antipsychotics; and (e) clinical
monitoring alone or coupled with crisis management (38, 40).
Cognitive Behavioral Therapy, French and Morrison
Protocol (CBT-F)
The CBT-F protocol (41), like the majority of CBT protocols,
is grounded on the principles established by Beck (42).
The intervention is problem-focused and time-limited, with
treatment strategies selected based on the formulation of each
patient’s presenting problems but from a range of permissible,
manualized strategies. Although each person’s therapy will be
tailored to their presenting needs, the core components include
building engagement, collaborative goal-setting and formulation,
normalizing psychotic-like experiences, evaluating core beliefs,
and different types of behavioral experiments (41, 43).
Cognitive Behavioral Therapy, van der Gaag Protocol
(CBT-V)
The protocol developed by van der Gaag et al. (44) is based
on the French and Morrison protocol (41), which is then
expanded by the addition of two novel components that target
cognitive biases. The first additional component is education on
dopamine system super-sensitivity and its relation to attenuated
psychotic symptoms and exaggeration of cognitive biases, with
the aim of normalizing aberrant perceptual experiences and
reducing associated distress. The individual is taught how
biases in cognition, such as selective attention, confirmation
bias and jumping-to-conclusions contribute to the formation of
delusions and paranoia (44). The second component involves
exercises/behavioral experiments to correct these biases through
examination of initial appraisals and testing of alternative
explanations (45). Further aims of CBT-V include supporting
school attendance and employment, improving relationships
with friends and relatives, and if applicable, reducing cannabis
use (44).
Integrated Psychological Interventions, Bechdolf
Protocol (IPI)
The protocol developed by Bechdolf et al. (46) is a multi-
component package of care. In addition to manualized
and time-limited individual CBT-F (41), IPI also includes
manualized group skills training, which focuses on scheduling
and monitoring leisure activities, training in social skills,
problem-solving and mastery of difficult situations, and
developing “keeping well” strategies (46). The third component
was computerized cognitive remediation to address thought and
perception deficits (basic symptoms), and a final component
included multi-family psychoeducation group sessions, which
aimed to reduce interpersonal conflict and associated stress by
helping family members better understand the CHR-P state
(46, 47).
Family-Focused Therapy, Miklowitz Protocol (FFT)
The family-focused therapy (FFT) protocol by Miklowitz et al.
(28) was originally developed for individuals with or at risk
of bipolar disorder. The FFT was then adapted for CHR-
P individuals, which has three broad stages. The first stage
of FFT encompasses psychoeducation and the development
of a patient-family prevention plan, which helps to increase
understanding of the stressors contributing to attenuated positive
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and negative symptoms, while also detailing coping strategies
and behavioral activation goals. The second stage focuses on
enhancing constructive patient-family communication, and the
third stage consists of improving problem-solving skills (28).
Psychopharmacological Interventions
Pharmacological interventions included licensed medications,
experimental pharmacotherapies as well as nutritional
supplements.
Placebo
The placebo component was reserved for pharmacological
placebos administered in the control arms of randomized
controlled trials.
Node Composition
We carefully identified the specific interventions (as listed above)
for each arm of every study, which were then linearly combined
to compose the precise treatment “nodes” of our network.
As discussed above, this definition of nodes is an essential
prerequisite for performing a robust NMA that can be of clinical
relevance. Each pharmacological treatment was assigned to its
own node, but different dosages of the same molecule were
categorized within the same node. While placebo was initially
considered as a separate node from NBI, after performing
sensitivity analyses to explore the effect of pooling them together,
we decided to combine them in the same node (see below for
details).
Search Strategy and Selection Criteria
The first step of our literature search involved systematic
electronic searches in the Web of Science (which includes Web
of Science Core Collection, BIOSIS Citation Index, KCI-Korean
Journal Database, MEDLINE, Russian Science Citation Index
and SciELO Citation Index) and Ovid/ PsychINFO databases,
the Cochrane Central Register of Controlled Trials and the
NHS Centre for Reviews and Dissemination (CRD), using the
following keywords: (risk OR prodromal OR prodrom∗ OR
ultra-high risk OR clinical high risk OR high risk OR genetic
high risk OR at risk mental state OR risk of progression OR
progression to first-episode OR prodromally symptomatic OR
basic symptoms) AND (psychosis) AND (RCT OR randomized
controlled trial OR placebo controlled trial OR trial). The
searches were conducted up to 18th July 2017 and no language
restrictions were applied. In a second step, we used Scopus/Web
of Science to screen the reference lists of articles identified in
the previous step and those of existing systematic reviews and
meta-analyses. For comprehensiveness, we also searched the
reference lists of relevant clinical guidelines. In a third step,
we looked for published and unpublished material in relevant
conference proceedings, trial registries (e.g., https://clinicaltrials.
gov) or regulatory agencies. The OpenGrey database (http://
www.opengrey.eu) was used to identify unpublished material
from the gray literature.
The above search strategies led us to identifying potential
abstracts of interest. The abstracts were then screened for
potential inclusion and those that survived this initial filter
were downloaded as full-text articles. These were then carefully
inspected against the full inclusion and exclusion criteria which
are described below.
In line with the PRISMA guidance, two independent
researchers conducted the literature search, study selection and
data extraction (48). During the above steps, disagreement
between extractors was addressed through discussion with a third
researcher until consensus was obtained. We defined the specific
inclusion and exclusion criteria to ensure that the population
represented in the final database would be broadly representative
of the target CHR-P population as a whole (49).
Our inclusion criteria were (a) being an original article,
abstract or pilot study; (b) being a randomized controlled trial
(including cluster randomized trials, but excluding cross-over
studies); (c) being designed as blinded (either single- or double-
blind); (d) being conducted in CHR-P individuals with CHR-P
criteria ascertained through the use of internationally validated
psychometric assessments, i.e., the Comprehensive Assessment of
At-Risk Mental States (CAARMS) (6), the Structured Interview
for Psychosis-risk Syndromes (SIPS) (50), the Positive and
Negative Syndrome Scale (PANSS) (51), the Brief Psychiatric
Rating Scale (BPRS) (52), or the Early Recognition Inventory
(ERIraos) (53); (e) comparing specific preventive interventions
as defined in the sections above; (f) providing sufficient data to
perform meta-analytic computation; (g) providing a sample size
of 10 or greater (54).
Our exclusion criteria were defined as (a) being a review or
reporting non-original data; (b) lacking at least two compared
groups, such as open-label trials in a single group of CHR-
P patients exposed to treatment; (c) investigating patient
samples affected with an established first-episode psychosis
or any at-risk group other than CHR-P samples; (d) lacking
sufficient data needed to perform the essential meta-analytical
computations; (e) design lacking proper randomization, such
as quasi-randomization or observational naturalistic studies -
however, studies that were initially conceived and designed
as blinded but could not maintain blinding during follow-up
(e.g., for psychological interventions) were not excluded; (f)
including a sample size smaller than 10 (i.e., N = 9 or less); (g)
presenting overlapping data (i.e., for the same outcome at the
same time point as data that was already included)-in the case
of overlapping data/samples, we preferred the data relating to the
largest sample size.
Outcome Measures and Data Extraction
Due to the variable effect of time on clinical outcomes in these
samples (9, 55), analyses for time-dependent outcomes were
conducted. The primary outcome (efficacy) was the level of
attenuated positive psychotic symptoms at follow-up, indexed
by the relevant subscales of validated assessments, such as the
PANSS, CAARMS, BPRS and SIPS. For each arm of every
study, we extracted the mean and standard deviation (SD) of
these scores at 6 and 12 month follow-up time points. Where
studies did not report sufficient data to extract the primary
outcome, we used DigitizeIt software (http://www.digitizeit.de/)
to extract data presented graphically (means and 95% confidence
intervals (CIs) for each follow-up time point). When necessary,
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SDs were back-calculated using standard formulae. If none of
the aforementioned were available, we estimated follow-up data
using information available from the published paper and using
assumptions established in previous literature. Sample sizes were
based on the numbers randomized to each arm.
A high benefit-to-harm ratio is essential when adopting
preventive strategies that may lead to the unnecessary treatment
of false positives. We therefore selected the acceptability
of interventions (discontinuation due to any cause) as our
secondary outcome measure. In line with previous authoritative
publications, we defined the acceptability of interventions as
the number of participants who dropped out of each arm for
any reason following randomization, over those randomized at
baseline (56–58).
In order to describe our population, assess the transitivity
assumption (see below), address the risk of bias and conduct
meta-regression analyses, we also extracted details on the
first author and year of publication of each trial, country
where the trial was conducted, types of outcomes reported,
definitions of intervention and control arms (in line with the
treatment components described above), trial design, risk of
bias assessment, duration of each intervention and follow-up,
sample size, mean age, percent male, and the psychometric CHR-
P instrument used to ascertain attenuated positive psychotic
symptoms.
Risk of Bias
The assessment of bias is of paramount importance for rigorously
interpreting the results of evidence synthesis studies and for
testing their robustness. We used the Cochrane Risk of Bias
tool (59) to classify the risk of bias in each study using a priori
defined criteria. Using these standardized criteria, we evaluated
whether each trial was at high, low or unclear risk of bias
across six specific domains. These included random sequence
generation, allocation concealment, blinding of participants and
study personnel, blinding of outcome assessments, incomplete
outcome data, and selective outcome reporting. Once these
domains were assessed, the Cochrane Risk of Bias tool allowed
production of an overall risk of bias classification of high, low or
unclear. The overall rating of low risk was assigned when none of
the six domains were found to be at high risk and if three or less
domains were found to be at unclear risk. The overall rating of
moderate risk was assigned when one domain was found to be at
high risk; or no domains were found to be at high risk but four or
more were found to be at unclear risk. In all other cases, the trial
was classified as having an overall high risk of bias (60).
Statistical Analysis
Network Meta-Analysis
Frequentist NMAs were conducted for both primary (attenuated
positive psychotic symptoms) and secondary (acceptability)
outcomes at 6 and 12 months using the network package in
STATA (version SE 14.2). Effect sizes for the primary outcome
were calculated and reported as the standardized mean difference
Hedges’ adjusted g (SMD) and 95% CIs in mean follow-up scores
between two compared interventions, using the pooled SD at
follow-up (61). Follow-up data are considered preferable when
measuring continuous outcomes that are difficult to measure
(62). Effect sizes for the secondary outcomewere reported as odds
ratio (OR) and 95% CIs. We first constructed network plots -
for each outcome- to ensure that the geometry of the networks
were sufficiently connected (63, 64). We then performed a NMA
assuming consistency and a common heterogeneity across all
comparisons in the network. This allowed us to derive a single
summary treatment effect (SMD for attenuated positive psychotic
symptoms; OR for acceptability) for every possible pairwise
comparison of treatments. This summary effect draws on all
evidence from the network of trials, including direct and indirect
evidence. Correlations in effect sizes induced by multi-arm trials
were accounted for (63, 65). The resulting relative SMDs or ORs
with 95% CIs for each pair of treatments were reported in league
tables (66). Statistical significance was set at p< 0.05.
When performing NMA it is possible to rank an outcome
of interest using the Surface Under the Cumulative RAnking
curve (SUCRA) procedure. Such an approach allows integration
of both the location and the variance of any relative effect
on the outcome of interest (67). In simple terms, the SUCRA
procedure summarizes the overall ranking of each intervention
through a single number ranging from 0 to 100% (68). In
this manuscript, the higher the SUCRA value, the higher the
likelihood that an intervention will be in the top rank, and
vice versa (68). In line with our objective, we performed cluster
ranking (63, 67) of the SUCRA values for attenuated positive
psychotic symptoms and acceptability (at 6 and 12 months,
separately) and presented the results in two-dimensional plots
(64). These plots aid visualization of the relative balance between
a treatment’s ranking across different outcomes, and show the
clustering of treatments into meaningful groups as determined
by hierarchical cluster analysis (63, 64).
Consistency in a network refers to the equivalence of direct
and indirect estimates of the same treatment comparison pairs,
and can be investigated in each closed loop of evidence (66). We
assessed this assumption by calculating an inconsistency factor
along with 95% CIs (truncated at 0) and associated p-values for
each closed loop of the primary outcome (63). Inconsistency was
defined as disagreement between direct and indirect evidence,
with 95% CIs for inconsistency factors excluding zero. Because
the loop-specific approach focuses on local inconsistency and
has low power, we also tested a full design-by-treatment model
(69) for the primary outcome to evaluate global inconsistency.
This entailed performing a NMA under the inconsistency model
and using the χ2-test to estimate the statistical significance of all
possible inconsistencies in the networks (70).
Transitivity was examined by assessing the distributions of
potential effect modifiers across comparisons in the networks.
These effect modifiers encompassed the following items: percent
male, age, percent exposed to antipsychotic medications at
baseline, type of blinding and publication year.
The presence of small-study effects was assessed by visual
inspection of comparison-adjusted funnel plots (71). In this
analysis we used NBI (or when not available, CBT-F + NBI) as
the reference. We assumed that small-study effects, if present,
would be expected to exaggerate the effectiveness of the “active”
(or newer/experimental) treatment, rather than NBI or CBT-F
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+ NBI, which currently represent the most widely implemented
interventions for this patient group.
Complementary Analyses
Sensitivity analyses were performed to address the impact of
study quality and our data analysis strategy. Specifically, we
repeated the NMA analyses on attenuated positive psychotic
symptoms using only: (a) studies with a low risk of bias for the
blinding of attenuated positive psychotic symptom assessments;
(b) studies whose meta-analytical data (i.e., mean and SD of
attenuated positive psychotic symptoms) were not estimated
using assumptions established in previous literature; and (c)
published trials only (i.e., excluding conference proceedings).
In addition, we repeated the NMA after pooling NBI and
placebo nodes and after pooling different types of antipsychotic
molecules. To ensure that the use of follow-up scores did not
unduly influence our results, we repeated the analyses using SMD
calculated from change score and pooled baseline SD, which
is recommended when a full ANCOVA model is not feasible
(62). Furthermore, we complemented the sensitivity analyses
through network meta-regression analyses. These were planned
only when substantial heterogeneity was observed and when at
least 10 independent trials were available (72) for each outcome
of interest. These meta-regressions were planned to investigate
the potential impact of the different CHR-P psychometric
instruments used for measuring attenuated positive psychotic
symptoms (34).
For the primary outcome, we also conducted conventional
pairwise meta-analyses (random effects model) of every direct
treatment comparison using the metan package in STATA. The
random effects meta-analyses were stratified by (a) follow-up
time (6 or 12months), and (b) pairwise intervention comparisons
(i.e., each type of treatment vs. its control was treated as
a meta-analysis, no overall summary effect computed across
comparisons of different treatments). The resultingmeta-analytic
SMDs together with 95% CIs and measures of heterogeneity (I2)
were calculated and presented in tables. When pairwise groups
had more than three contributing studies, we performed leave-
one-out sensitivity analyses to explore the robustness of the
results to influential individual studies.
RESULTS
Characteristics of Trials and Patients
Our initial literature search identified 1,556 references. However,
most of them did not report on RCTs in CHR-P individuals. As
indicated in Figure 1, 49 of them were eventually downloaded
and fully inspected against the inclusion and exclusion criteria,
which resulted in a final sample of 14 studies. We found only
three, three, two and two trials reporting the outcome data of
interest at 18, 24, 36, and >36 month time points, respectively.
Consequently, the current meta-analysis focuses only on the 6
and 12 month time points. The 14 studies used in the analyses
contributed data on a total of 1707 patients, with a mean age
of 20.1 ± 2.9 years, and of whom 57% were male (Table 1).
The mean sample size was 122 (range 44–304). Five studies
were conducted in North America, five in Europe, three in
Australia and one was multi-national. Two trials adopted a three-
arm design while all of the others employed a two-arm design.
Two of the included studies were identified from conference
proceedings and gray literature/clinical trial databases (24, 30).
Two studies had a treatment duration of <6 months, eight
of 6 months, and four of 12 months. Three of the 12 trials
that reported enough information to identify the source of
sponsorship or funding acknowledged pharmaceutical company
involvement. The SIPS was the most common assessment used
for measuring attenuated positive psychotic symptoms (N = 6).
Only two studies had an overall low risk of bias (30, 40),
four had unclear risk (24, 26, 27, 73) and the remaining eight
had high risk; the full risk of bias assessment is presented in
Figure 2.
For the primary outcome, eight studies provided data for
both 6 and 12 month networks, three only provided data for 6
months, and another 3 only for 12 months, resulting in 11 studies
contributing data for the 6 month analysis, and 11 to the 12
month analysis. For the 6 month analysis, 11 studies (N = 1459)
provided data on 15 direct comparisons between 8 different
treatment nodes (Figure 3A). For the 12 month analysis, 11
studies (N = 1483) provided data on 15 direct comparisons
between 7 different treatment nodes (Figure 3B).
At 6 months, seven studies provided the required follow-
up symptom data directly or indirectly, two provided means
and SD graphically (28, 40), and for two studies symptom data
were estimated on the basis of available data and assumptions
established in previous literature (27, 30). At 12 months, nine
studies provided the required data directly or indirectly, one
provided data graphically (40), and for one study symptom data
were estimated on the basis of available data and assumptions
established in previous literature (27).
All studies, except one (38), provided data for the secondary
outcome (acceptability) at both 6 and 12 months. Network plots
for the acceptability outcome were the same as those for the
primary outcome (Figure 3).
Pairwise Meta-Analysis
Pairwise meta-analysis results for the primary outcome are
presented in Table 2. Only three pairwise intervention vs. control
groups had two or more studies: CBT-F + NBI vs. NBI; omega-
3 + NBI vs. NBI; and risperidone + CBT-F + NBI vs. NBI.
The remaining pairwise intervention vs. control groups were
composed of single studies.
At 6 months, there was no significant difference between
CBT-F + NBI vs. NBI alone (SMD = −0.06, 95% CI −0.26 to
0.13; 5 studies, N = 652). However, there was meta-analytical
evidence of a greater reduction in attenuated positive psychotic
symptoms in CBT-F + NBI vs. NBI alone at 12 months
(SMD = −0.22, 95% CI −0.37 to −0.07; 6 studies, N = 712).
Leave-one-out sensitivity analyses showed that this effect was
dependent on the presence of one study (74). When this study
was removed, the combined effect at 12 months became non-
significant (SMD = −0.12, 95% CI −0.32 to 0.08; 5 studies,
N = 424). The non-significant summary effect at 6 months did
not become significant throughout any iteration of the leave-one-
out analyses.
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FIGURE 1 | PRISMA flow chart of the study selection process. CHR-P, clinical high risk for psychosis; RCT, randomized controlled trial.
Two studies compared omega-3+NBI to NBI alone, but both
6 and 12 month summary effect estimates were not significant
(6 month SMD = −0.48, 95% CI −1.62 to 0.67, 2 studies,
N = 385; 12 month SMD = −0.38, 95% CI −1.38 to 0.63, 2
studies,N = 385). Significant heterogeneity was detected between
these two studies at both 6 (I2 = 95%, p < 0.001) and 12
(I2 = 94%, p< 0.001) month time points. Statistical investigation
of potential sources of heterogeneity using meta-regression was
precluded by the limited number of studies.
Combined therapy with risperidone + CBT-F + NBI was not
significantly different from NBI alone at either 6 (SMD = 0.02,
95% CI −0.33 to 0.37, 2 studies, N = 130) or 12 months
(SMD = 0.00, 95% CI −0.38 to 0.38, 2 studies, N = 130). While
available data on all further pairwise treatments vs. controls are
listed in Table 2 for completeness, they represent single studies
and thus cannot be considered meta-analytic results.
Network Meta-Analysis – Effect on
Attenuated Positive Psychotic Symptoms
Results of the NMA are presented in Tables 3, 4. At 6 months,
ziprasidone + NBI was found to be significantly more effective
at reducing attenuated positive psychotic symptoms compared to
NBI alone (SMD = −1.10, 95% CI −2.04 to −0.15); compared
to CBT-F + NBI (SMD = −1.03, 95% CI −2.05 to −0.01); and
compared to risperidone + CBT-F + NBI (SMD = −1.18, 95%
CI −2.29 to −0.07). There were no other significant effects of
any one intervention over any others (Table 3). Using NBI as a
comparator, the relative treatment effect estimates (all SMD < 0
favor the given treatment) at 6 months were: ziprasidone +
NBI (SMD = −1.10, 95% CI −2.04 to −0.15); omega-3 +
NBI (SMD = −0.42, 95% CI −1.01 to 0.16); aripiprazole +
NBI (SMD = −0.18, 95% CI −0.90 to 0.53); family-focused
therapy + NBI (SMD = −0.41, 95% CI −1.22 to 0.41); CBT-F
+ NBI (SMD = −0.07, 95% CI −0.44 to 0.31); D-serine + NBI
(SMD=−0.10, 95% CI−1.05 to 0.84); and risperidone+ CBT-F
+ NBI (SMD= 0.08, 95% CI−0.50 to 0.67).
At 12months, there was no evidence that any one intervention
was superior over any others, with all 95% CIs crossing zero
(Table 4). Using NBI as a comparator, the relative treatment
effect estimates (all SMD < 0 favor the given treatment) at 12
months were: olanzapine + NBI (SMD = −0.53, 95% CI −1.28
to 0.22); omega-3 + NBI (SMD=−0.30, 95% CI−0.77 to 0.17);
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TABLE 1 | Characteristics of included studies.
Study Study arms (N) Total
N
Network
inclusion
Treatment
duration
(months)
Follow-up
time
points
(months)
%
male
Mean
age
Measure of
symptoms
Study
design
Country % exposed to
antipsychotics
at baseline
Addington et al. (37) CBT-F + NBI [27]
NBI [24]
51 6, 12 6 6, 12, 18 71 20.9 SIPS SB-RCT Canada 0
Amminger et al. (40) Omega-3 + NBI [41]
NBI [40]
81 6, 12 3 6, 12, 84 33 16.4 PANSS DB-RCT Austria 0
Bechdolf et al.
(46, 75)
IPI [63]
NBI [65]
128 12 12 6, 12, 18,
24
63 26.0 PANSS SB-RCT Germany 0
Bechdolf et al. (24) ARI + NBI [96]
NBI [55]
CBT-F + NBI [129]
280 6, 12 12 6, 12 66 24.4 SIPS SB-RCT Germany 3.4
Kantrowitz et al. (26) D-serine + NBI [20]
NBI [24]
44 6 4 4 66 19.4 SIPS DB-RCT US 11.4
McGlashan et al. (73) OLA + NBI [31]
NBI [29]
60 12 12 12, 24 65 17.7 SIPS DB-RCT US, Canada 10
McGorry et al. (38) RIS + CBT-F + NBI [31]
NBI [28]
59 6, 12 6 6, 12,
36–48
58 20.0 BPRS SB-RCT Australia 0
McGorry et al. (27) Omega-3 + NBI [153]
NBI [151]
304 6, 12 6 6, 12 46 19.2 BPRS DB-RCT Multi-national 0
Miklowitz et al. (28) FFT + NBI [66]
NBI [63]
129 6 6 6 57 17.4 SIPS SB-RCT US, Canada 20.9
Morrison et al. (43) CBT-F + NBI [37]
NBI [23]
60 12 6 6, 12, 36 69 22.0 PANSS SB-RCT UK 0
Morrison et al. (74) CBT-F + NBI [144]
NBI [144]
288 6, 12 6 6, 12, 18,
24
63 20.7 CAARMS SB-RCT UK 0
Stain et al. (29) CBT-F + NBI [30]
NBI [27]
57 6, 12 6 6, 12 40 16.3 CAARMS SB-RCT Australia 0
Woods et al. (30, 31) ZIP + NBI [24]
NBI [27]
51 6 6 6 64 22.3 SIPS DB-RCT US 0
Yung et al. (76) and
McGorry et al. (77)
CBT-F + NBI [44]
RIS + CBT-F + NBI [43]
NBI [28]
115 6, 12 12 6, 12 39 18.1 BPRS SB-RCT Australia 0
CBT-F, cognitive behavioral therapy (French and Morrison protocol); NBI, eeds-based interventions (including placebo); IPI, integrated psychological interventions; ARI, aripiprazole;
OLA, olanzapine; RIS, risperidone; FFT, family-focused therapy; ZIP, ziprasidone; SIPS, Structured Interview for Psychosis-risk Syndromes; PANSS, Positive and Negative Syndrome
Scale; BPRS, Brief Psychiatric Rating Scale; CAARMS, Comprehensive Assessment of At-Risk Mental States; SB-RCT, single-blind randomized controlled trial; DB-RCT, double-blind
randomized controlled trial.
aripiprazole+NBI (SMD=−0.23, 95% CI−0.78 to 0.33); CBT-
F + NBI (SMD = −0.15, 95% CI −0.43 to 0.13); risperidone
+ CBT-F + NBI (SMD = −0.04, 95% CI −0.52 to 0.44); and
integrated psychological interventions (SMD = 0.20, 95% CI
−0.45 to 0.84).
Inconsistency and Small-Study Effects
There was no statistically significant inconsistency in the 6 or 12
month networks. The 95% CIs for all inconsistency factors were
compatible with zero inconsistency. However, it is important to
note that only two loops were available at both 6 and 12 months,
which may have limited our ability to detect inconsistency.When
we used the design-by-treatment interaction model, there was no
evidence for significant inconsistency in the 6 (p = 0.92) or 12
month (p= 0.92) networks.
Visual inspection of comparison-adjusted funnel plots
suggested no clear small-study effects (publication biases),
with a regression line almost flat at 6 months (Figure S1A in
Supplementary Material) and completely flat at 12 months
(Figure S1B in Supplementary Material).
Sensitivity Analyses for NMA of Primary Outcome
We tested the robustness of the core NMA findings (that
ziprasidone + NBI is superior to NBI alone, CBT-F + NBI,
and risperidone + CBT-F + NBI at 6 months) through various
sensitivity analyses. At 6 months, two studies (27, 30) were
based on estimated follow-up data, one of which was the single
ziprasidone + NBI vs. NBI study (30). Repeating the analyses
after removal of the latter study (30) inherently meant that there
was now no ziprasidone+ NBI node and all estimates were non-
significant. Removal of the other study -by McGorry et al (27)-
did not affect the current results at 6 or 12 months; however,
one change of note is that at 12 months, CBT-F + NBI became
significantly more effective than NBI, which is interesting in light
of the pairwise significance of CBT-F+NBI vs. NBI at 12months,
and lack thereof in the main NMA analyses.
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FIGURE 2 | Risk of bias summary. Review authors’ judgements about each risk of bias item for each included study. Green circles (+) indicate low risk of bias; yellow
circles (?) indicate unclear risk; red circles (−) indicate high risk of bias.
The ziprasidone+NBI results were not robust to the removal
of two studies (38, 76) at high or unclear risk of bias for the
blinding of outcome assessments, which resulted in only the
ziprasidone + NBI vs. NBI comparison remaining significant.
Repeating the analyses after removing unpublished studies (24,
30), pooling together different antipsychotic molecules, and
using change scores instead of follow-up scores all abolished
the ziprasidone + NBI results. Repeating the analyses treating
NBI + placebo as a separate node to NBI had some effect
on the NMA estimates at 6 months (ziprasidone + NBI was
now superior only to NBI + placebo) and had no effect at 12
months; we therefore used the pooled NBI + placebo in the
main analysis (Tables 1–4, Figures 3, 4). There were too few
studies to allow robust meta-regression analyses on the type
of instruments used to measure attenuated positive psychotic
symptoms.
Network Meta-Analysis – Effect on
Acceptability
There were no significant differences in acceptability between any
treatments at 6 months (Table 3). At 12 months, aripiprazole
+ NBI was significantly more acceptable than olanzapine +
NBI (OR = 3.73; 95% CI 1.01 to 13.81). There were no
further significant differences at 12 months (Table 4). However,
at both time points, the 95% CIs for the comparisons were
often very wide, indicating substantial imprecision in the
estimates.
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FIGURE 3 | Network plots of direct comparisons at 6 (A) and 12 (B) months.
The width of the lines is proportional to the number of trials comparing each
pair of treatments and the size of each node is proportional to the number of
studies testing the specific treatment. Numbers represent the number of
studies contributing data to each comparison. ARI, aripiprazole; NBI,
needs-based interventions (including placebo); CBT-F, cognitive behavioral
therapy (French and Morrison protocol); Dser, D-serine; FFT, family-focused
therapy; Om3, omega-3 fatty acids; RIS, risperidone; ZIP, ziprasidone; IPI,
integrated psychological interventions; OLA, olanzapine.
Network Meta-Analysis – Cluster Ranking
for Attenuated Positive Psychotic
Symptoms and Acceptability
The cluster ranking plots of SUCRA values for attenuated positive
psychotic symptoms (efficacy) and acceptability are illustrated
in Figure 4A (for 6 months) and Figure 4B (for 12 months).
However, it should be noted that although the treatments were
cluster ranked, there was no statistically significant difference
between any treatments (with the exception of ziprasidone +
NBI) in the main network meta-analysis results (see Tables 3, 4
for details).
Three distinct clusters were found in the cluster ranking at
6 months (Figure 4A). Notably, while ziprasidone + NBI had
the highest SUCRA for efficacy (94%), it was also the most
poorly tolerated, having the lowest SUCRA value for acceptability
(23%). In a second cluster, omega-3 + NBI and family-focused
therapy + NBI had similar SUCRA scores for efficacy (67%
and 63%, respectively), however, they differed markedly in their
SUCRA for acceptability; family-focused therapy + NBI had
the highest acceptability SUCRA of all treatments (70%), while
that of omega-3 + NBI was mid-range (49%). The third cluster
comprised the remaining treatments, whose SUCRA values for
efficacy were all below 50%, but whose acceptability SUCRAs
varied from 62% for aripiprazole + NBI, to 37% (the worst) for
NBI.
At 12 months, four distinct clusters were found (Figure 4B).
Similar to above, while olanzapine + NBI was ranked highest
of all treatments for efficacy SUCRA (82%), it also scored
worst for acceptability (13%). A second cluster, with a more
balanced profile of efficacy and acceptability SUCRA values,
comprised aripiprazole + NBI, omega-3 + NBI and CBT-F
+ NBI. Of these, omega-3 + NBI had the highest SUCRA
value in terms of efficacy (70%) but lower acceptability (57%),
aripiprazole + NBI had slightly lower efficacy (60%) but
the highest acceptability of all treatments (91%), and CBT-
F + NBI had mid-range values for both outcomes. NBI and
risperidone + CBT-F + NBI were found in a third, intermediate
cluster with low mid-range SUCRA values. The final cluster
was composed of integrated psychological interventions, with
SUCRA values of 19% and 26% for efficacy and acceptability,
respectively.
DISCUSSION
To the best of our knowledge, this is the first network meta-
analysis to have explored the effect of preventive treatments on
attenuated positive psychotic symptoms in CHR-P individuals.
Focusing exclusively on RCTs to minimize selection biases, we
included a total of 14 non-overlapping studies, for a total database
of 1,707 CHR-P individuals, representing the largest evidence
synthesis of this topic to date. By using themost updated evidence
we defined two networks at 6 and 12 months, on which we
performed the core analyses. These two networks included 8 and
7 nodes, respectively. There were not enough studies to generate
networks beyond these time points. Overall, our network meta-
analyses indicated no robust evidence of superior efficacy for any
specific intervention on attenuated positive psychotic symptoms
at any time point, with the exception of ziprasidone + NBI,
which was superior to NBI alone, CBT-F+ NBI, and risperidone
+ CBT-F + NBI. However, the evidence specifically relating to
ziprasidone + NBI was based on a single study only and did
not survive sensitivity analyses. The results were not affected
by inconsistency or evident small-study effects (publication
biases).
The main finding of the current study is that there is a lack
of evidence to favor specific effective interventions for reducing
attenuated positive psychotic symptoms in CHR-P individuals.
While ziprasidone+NBI demonstrated some superiority in the 6
month network meta-analyses, these results are not robust. First,
the efficacy of ziprasidone + NBI comes from only one as-yet
unpublished study. Second, the results did not survive most of
the sensitivity analyses. Finally, in the cluster ranking, it was clear
that while ziprasidone+NBIwas themost efficacious in reducing
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TABLE 2 | Pairwise meta-analytic results for attenuated psychotic symptoms at 6 and 12 months.
Time point;
months
Treatment
condition
Control
condition
Number of studies
(references)
Total N SMD (g) Lower 95%CI Upper 95%CI Heterogeneity
Treatment Control I2 Q P
6 ARI + NBI NBI 1 (24) 96 55 −0.22 −0.56 0.11 – 0.00 –
ARI + NBI CBT-F+NBI 1 (24) 96 129 −0.06 −0.33 0.20 – 0.00 –
CBT-F + NBI NBI 5 (24, 29, 37, 74, 76) 374 278 −0.06 −0.26 0.13 24.2 5.27 0.26
Dser + NBI NBI 1 (26) 20 24 −0.10 −0.70 0.49 – 0.00 –
FFT + NBI NBI 1 (28) 66 63 −0.41 −0.76 −0.06 – 0.00 –
Om3 + NBI NBI 2 (27, 40) 194 191 −0.48 −1.62 0.67 94.8 19.4 <0.001
RIS + CBT-F + NBI CBT-F+NBI 1 (76) 43 44 0.37 −0.05 0.80 – 0.00 –
RIS + CBT-F + NBI NBI 2 (38, 76) 74 56 0.02 −0.33 0.37 0.00 0.72 0.40
ZIP + NBI NBI 1 (30) 24 27 −1.10 −1.69 −0.50 – 0.00 –
12 ARI + NBI NBI 1 (24) 96 55 −0.22 −0.55 0.12 – 0.00 –
ARI + NBI CBT-F+NBI 1 (24) 96 129 −0.08 −0.34 0.18 – 0.00 –
CBT-F + NBI NBI 6 (24, 29, 37, 43, 74, 77) 411 301 −0.22 −0.37 −0.07 0.00 3.27 0.66
IPI NBI 1 (46) 63 65 0.20 −0.15 0.54 – 0.00 –
OLA + NBI NBI 1 (73) 31 29 −0.53 −1.05 −0.02 – 0.00 –
Om3 + NBI NBI 2 (27, 40) 194 191 −0.38 −1.38 0.63 93.5 15.49 <0.001
RIS + CBT-F + NBI CBT-F+NBI 1 (77) 43 44 −0.07 −0.49 0.35 – 0.00 –
RIS + CBT-F + NBI NBI 2 (38, 77) 74 56 0.00 −0.38 0.38 16.2 1.19 0.28
Underlined bold text within the SMD and 95% CI columns indicates statistically significant meta-analytic treatment effect. SMD below 0 favors the given treatment condition. ARI,
aripiprazole; NBI, needs-based interventions (including placebo); CBT-F, cognitive behavioral therapy (French & Morrison protocol); Dser, D-serine; FFT, family-focused therapy; Om3,
omega-3 fatty acids; RIS, risperidone; ZIP, ziprasidone; IPI, integrated psychological interventions; OLA, olanzapine. Dashes (–) indicate no heterogeneity estimate due to having only
one contributing study (and thus cannot be considered a true meta-analytic result).
attenuated positive symptoms, it was poorly tolerated with the
lowest ranking for acceptability. Similarly, the only significant
result in pairwise analyses was for CBT-F + NBI vs. NBI at 12
months. Again, this was found to be reliant on the inclusion
of one particular study (74) in sensitivity analyses. Given that
the data relating to the CBT-F + NBI element are identical
in both the pairwise and network meta-analyses, the driving
factor for the disparity (in significance of CBT-F + NBI vs.
NBI in pairwise vs. network meta-analyses) likely emerges from
the additional data about NBI that the NMA had gained from
the rest of the network (i.e., the relative effectiveness of NBI as
derived indirectly from the other -direct- comparisons). Support
for this explanation comes from the finding that, when one
particular study (27) was removed from the 12 month network
(in sensitivity analyses), the CBT-F + NBI vs. NBI comparison
became significant. Inspection of the data for this removed study
(27) showed that it had the largest NBI arm (N = 151) of all
trials, and although the study-specific SMD was not significant,
the SMD was favoring NBI over the comparative intervention
(omega-3 + NBI). This suggests that the relative effectiveness
of NBI may have been underestimated by the direct (pairwise)
CBT-F + NBI vs. NBI estimates compared to the NMA-derived
estimates.
Overall, our negative results are concordant with several lines
of evidence pointing toward ineffective treatments for CHR-P
individuals. Beyond the lack of evidence for specific treatments
reducing the risk of developing psychosis -as determined by our
earlier study (22)-, another recently published network meta-
analysis found no evidence that any treatments were better
than any others in improving attenuated negative symptoms in
CHR-P individuals (78, 79). The lack of impact on attenuated
negative symptoms is in line with meta-analytical evidence
showing that full-blown negative symptoms are refractory to
any kind of treatment (72). More to the point, there is not
even evidence that current preventive treatments can ameliorate
clinical outcomes such as functional level (80–83), depressive
comorbidities (83), distress (81) and quality of life (81, 83) in
CHR-P individuals. It is possible that the lack of evidence for
effective treatments to reduce transition to psychosis may be
secondary to low statistical power for testing this outcome. In
turn, this can be caused by the recruitment strategies adopted
by recent RCTs that have focused on individuals that were
poorly risk enriched, causing a dilution of the final risk for
psychosis (23). On the contrary, the lack of evidence for effects
on attenuated positive psychotic symptoms cannot simply be
attributed to low statistical power. Rather, it is possible that
the available treatments are not disease-modifying because
they are not targeting the core pathophysiological processes
underlying the onset of psychosis in CHR-P individuals (3). It
is also possible that effective preventive treatments do exist, but
we are currently unable to detect them because of the large
noise and between-subject heterogeneity that is observed. For
example, the level of attenuated positive psychotic symptoms
varies considerably across different CHR-P subgroups. We have
previously found that CHR-P individuals meeting the short-
lived psychotic episode subgroup have the highest risk of
developing psychosis (about 40–50% at 2 years) (9, 84), those
meeting the attenuated psychotic symptoms subgroup have
an intermediate risk (about 20% at 2 years) (9), and those
meeting the genetic risk subgroup have a low risk (about
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TABLE 3 | Network meta-analytic relative treatment effects for efficacy and acceptability at 6 months.
ZIP + NBI 1.77
(0.32,9.79)
2.63
(0.42,16.68)
2.22
(0.39,12.75)
1.83
(0.24,13.78)
1.79
(0.40,8.07)
1.55
(0.38,6.27)
2.28
(0.34,15.09)
−0.67
(−1.78,0.44)
Om3 + NBI 1.49
(0.31,7.07)
1.26
(0.30,5.30)
1.04
(0.18,6.01)
1.01
(0.33,3.13)
0.88
(0.33,2.35)
1.29
(0.26,6.44)
−0.69
(−1.94,0.56)
−0.01
(−1.02,0.99)
FFT + NBI 0.84
(0.17,4.15)
0.69
(0.11,4.59)
0.68
(0.18,2.56)
0.59
(0.18,1.96)
0.87
(0.15,4.98)
−0.91
(−2.10,0.27)
−0.24
(−1.16,0.68)
−0.23
(−1.31,0.86)
ARI + NBI 0.82
(0.14,4.93)
0.80
(0.28,2.28)
0.70
(0.25,1.98)
1.03
(0.21,5.02)
−0.99
(−2.33,0.35)
−0.32
(−1.43,0.79)
−0.30
(−1.55,0.94)
−0.08
(−1.26,1.11)
Dser + NBI 0.98
(0.21,4.65)
0.85
(0.20,3.63)
1.25
(0.18,8.60)
−1.03
(−2.05,−0.01)
−0.36
(−1.05,0.34)
−0.34
(−1.24,0.56)
−0.11
(−0.82,0.59)
−0.04
(−1.05,0.98)
CBT–F + NBI 0.87
(0.50,1.51)
1.27
(0.36,4.46)
−1.10
(−2.04,−0.15)
−0.42
(−1.01,0.16)
−0.41
(−1.22,0.41)
−0.18
(−0.90,0.53)
−0.10
(−1.05,0.84)
−0.07
(−0.44,0.31)
NBI 1.47
(0.41,5.25)
−1.18
(−2.29,−0.07)
−0.50
(−1.33,0.32)
−0.49
(−1.49,0.51)
−0.26
(−1.16,0.63)
−0.18
(−1.30,0.93)
−0.15
(−0.78,0.48)
−0.08
(−0.67,0.50)
RIS + CBT-F
+ NBI
Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. For
the primary outcome (attenuated positive psychotic symptoms) estimates, results are SMD (95% CI), where SMD below 0 favors the column-defined treatment. For acceptability, results
are OR (95% CI), where OR < 1 favors the row-defined treatment. Significant results are in bold. The order of treatments in the diagonal is arbitrary and does not reflect ranking. ZIP,
ziprasidone; NBI, needs-based interventions (including placebo); Om3, omega-3 fatty acids; FFT, family-focused therapy; ARI, aripiprazole; Dser, D-serine; CBT-F, cognitive behavioral
therapy (French & Morrison protocol); RIS, risperidone.
Comparison.
Efficacy (attenuated psychotic symptoms; SMD [95% CI]).
Acceptability (dropout; OR [95% CI]).
TABLE 4 | Network meta-analytic relative treatment effects for efficacy and acceptability at 12 months.
OLA + NBI 2.31
(0.64,8.32)
3.73
(1.01,13.81)
2.39
(0.73,7.83)
1.98
(0.47,8.32)
2.31
(0.75,7.05)
1.38
(0.30,6.38)
−0.23
(−1.12,0.65)
Om3 + NBI 1.61
(0.64,4.07)
1.03
(0.50,2.12)
0.86
(0.29,2.53)
1.00
(0.53,1.86)
0.59
(0.18,2.02)
−0.31
(−1.24,0.63)
−0.07
(−0.80,0.66)
ARI + NBI 0.64
(0.32,1.26)
0.53
(0.18,1.57)
0.62
(0.31,1.22)
0.37
(0.11,1.29)
−0.38
(−1.19,0.42)
−0.15
(−0.70,0.40)
−0.08
(−0.63,0.47)
CBT-F + NBI 0.83
(0.35,2.00)
0.97
(0.64,1.45)
0.58
(0.19,1.78)
−0.49
(−1.39,0.40)
−0.26
(−0.93,0.41)
−0.19
(−0.90,0.53)
−0.11
(−0.62,0.40)
RIS + CBT-F
+ NBI
1.16
(0.47,2.86)
0.69
(0.17,2.76)
−0.53
(−1.28,0.22)
−0.30
(−0.77,0.17)
−0.23
(−0.78,0.33)
−0.15
(−0.43,0.13)
−0.04
(−0.52,0.44)
NBI 0.60
(0.21,1.71)
−0.73
(−1.72,0.26)
−0.50
(−1.30,0.30)
−0.42
(−1.28,0.43)
−0.35
(−1.05,0.36)
−0.24
(−1.04,0.57)
−0.20
(−0.84,0.45)
IPI
Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment.
For the primary outcome (attenuated positive psychotic symptoms) estimates, results are SMD (95% CI), where SMD below 0 favors the column-defined treatment. For acceptability,
results are OR (95% CI), where OR < 1 favors the row-defined treatment. Significant results are in bold. The order of treatments in the diagonal is arbitrary and does not reflect ranking.
OLA, olanzapine; NBI, needs-based interventions (including placebo); Om3, omega-3 fatty acids; ARI, aripiprazole; CBT-F, cognitive behavioral therapy (French & Morrison protocol);
RIS, risperidone; IPI, integrated psychological interventions.
Comparison.
Efficacy (attenuated psychotic symptoms; SMD [95% CI]).
Acceptability (dropout; OR [95% CI]).
3% at 2 years) (9). In a subsequent prospective cohort study,
we confirmed that CHR-P individuals meeting the short-lived
psychotic episode subgroup criteria have a very high risk
of developing persistent psychotic episodes (85). Additional
ongoing analyses revealed that these three subgroups are
associated with different clinical needs and use of mental health
services. These results led us to propose clinical stratification
of the CHR-P population across different subgroups (1), which
has been endorsed by other leading researchers in this area
(2, 86). However, because most trials were conducted before
such knowledge emerged, response to preventive treatment was
not stratified across these different subgroups and we have
been unable to control for this variable in meta-regression
analyses. The clinical heterogeneity of this population is further
amplified by the heterogeneous accumulation of risk factors
for psychosis (5), which is reflected in a variable enrichment
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FIGURE 4 | Cluster-ranking of treatments according to SUCRA values for
efficacy and acceptability at 6 (A) and 12 (B) months. Colors reflect treatments
belonging to the same cluster. Please note that although the treatments have
been ranked, there is no statistical difference between them -with the
exception of ziprasidone+NBI for efficacy- (see Tables 3,4 for further details).
ARI, aripiprazole; NBI, needs-based interventions (including placebo); CBT-F,
cognitive behavioral therapy (French and Morrison protocol); Dser, D-serine;
FFT, family-focused therapy; Om3, omega-3 fatty acids; RIS, risperidone; ZIP,
ziprasidone; IPI, integrated psychological interventions; OLA, olanzapine.
of risk to psychosis (17) and different clinical outcomes. The
latter may include the development of psychosis, persistence of
symptoms and comorbidities, or recovery (32). Overall, the above
considerations indicate that the “one-size-fits-all” approach to
offering preventative strategies to CHR-P individuals is unlikely
to work, namely due to the heterogeneity of the CHR-P state.
This raises the possibility that the available treatments have been
ineffective because they were applied to all CHR-P subjects,
rather than to stratified subgroups. For example, a true preventive
effect may be difficult to detect in those at low risk or in
those who are responding to placebo or low-level needs-based
interventions.
These findings may be informative for future research.
For example, they suggest that a stratified precision medicine
approach may improve the apparent effectiveness of available
treatments. Identifying specific factors that predict response
to preventive treatments at the individual subject level may
substantially advance clinical care for CHR-P individuals by
personalizing their preventive interventions. This could be
achieved using the existing RCT data under an individual
participant data network meta-analytic approach. These
advanced meta-analytical approaches allow the stratification
of treatment response through the development of predictive
risk estimation tools (87) and could potentially produce a
breakthrough advancement of clinical knowledge in this
area. Our research group has recently completed the protocol
for an individual participant data network meta-analyses
(PROSPERO 2018 CRD42018089161) which is due to start
imminently. At the same time, the lack of convincing
evidence for effective treatments should foster refreshed
collaborative efforts to test innovative novel treatments for
CHR-P individuals. It is important to note that challenges
in developing effective preventive treatments are not specific
to the CHR-P field but are common across other branches
of clinical medicine, such as in the prevention of dementia.
Promising compounds are on the horizon. For example, the
first ever industry-funded RCT for CHR-P individuals will
be investigating the efficacy of a phosphodiesterase inhibitor
to prevent psychosis (88). Of relevance, to partially reduce
the clinical heterogeneity discussed above, this RCT will
focus only on CHR-P individuals presenting with attenuated
positive psychotic symptoms and who are enriched in risk
as determined by a specific risk stratification algorithm (89).
Another promising candidate treatment is cannabidiol, which
was found to be well tolerated and reduced symptoms in
an early-phase trial in CHR-P individuals, although the
full report is not yet available (90, 91). A larger-scale RCT
of cannabidiol is due to start at our institute in the near
future. The discovery and development of more effective
treatments for attenuated positive psychotic symptoms also
requires an improved regulatory platform to reliably sustain
the next generation of research. For example, while the
DSM-5 includes a newly introduced diagnostic category for
attenuated psychosis syndrome (92), there will be no similar
diagnostic category in the ICD-11. Diagnostic controversies,
as well as different methods of ascertainment of attenuated
psychotic symptoms [for a comparative analysis of different
CHR-P instruments see (34)] are unlikely to facilitate the
large-scale collaborations that are necessary to overcome the
current limitations.
There are some important limitations to our work. First,
the interpretation of negative findings is always challenging. In
fact, as noted by leading authors, absence of evidence is not
evidence of absence (93). Such an observation is particularly
relevant in the case of large CIs, such as those that have been
observed in the current analyses (see Tables 3, 4). Therefore,
some sizeable effects may still have been missed by our analyses.
Furthermore, only 14 RCTs were included, reflecting the scarcity
of studies available in this field. Although network meta-analyses
are characterized by increased power and precision (94), the
geometry of the networks in the current study limited our
ability to test for inconsistency, and potentially resulted in more
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imprecise estimates and wide 95%CIs. An additional limitation is
that the overall quality of our networkmeta-analysis is dependent
on the quality of each included study, most of which were at
high or unclear risk of bias. We partially controlled for this
problem through assessment of biases and sensitivity analyses.
The final limitation concerns the use of dropout for any reason
as a proxy measure for acceptability. While this measure is
generally accepted in network meta-analyses of RCTs (56–58),
it is a rather crude and spurious outcome measure. The use
of a more specific side effect outcome could have revealed
more subtle differences in acceptability across the available
treatments. We have been unable to analyse any specific side
effects because these were infrequently reported in the available
literature.
CONCLUSIONS
In conclusion, on the basis of the most comprehensive evidence
synthesis to date, there is currently no robust evidence to
favor specific interventions for improving attenuated positive
psychotic symptoms in CHR-P individuals.
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